Payment overview · 2025
General Payments
$199.22
10 reported records · 5 companies
Healthcare provider profile · identity verified
Robert C Solomon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLACKSBURG, VA · NPI 1902864374
Verified facts
What the public records show
CMS Open Payments records show Robert C Solomon, MD received $199.22 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 311 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.31 | 36.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.21 | 33.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.28 | 11.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.91 | 11.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.51 | 7.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.22 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.21 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.69 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 311 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
311 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 98 |
| Valsartan | Valsartan | 333 | 87 |
| Eliquis | Apixaban | 311 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 298 | 59 |
| Simvastatin | Simvastatin | 266 | 76 |
| Omeprazole | Omeprazole | 250 | 71 |
| Furosemide | Furosemide | 247 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 51 |
| Gabapentin | Gabapentin | 190 | 55 |
| Potassium Chloride | Potassium Chloride | 181 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 58 |
| Alprazolam | Alprazolam | 166 | 22 |
| Lisinopril | Lisinopril | 166 | 49 |
| Ozempic | Semaglutide | 164 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 159 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 40 |
| Metformin Hcl | Metformin Hcl | 146 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 52 |
| Losartan Potassium | Losartan Potassium | 139 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 36 |
| Tramadol Hcl | Tramadol Hcl | 138 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 130 | 43 |
| Clonazepam | Clonazepam | 120 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 20 |
| Lorazepam | Lorazepam | 120 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 106 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 106 | 28 |
| Carvedilol | Carvedilol | 103 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 23 |
| Prednisone | Prednisone | 94 | 39 |
| Clonidine Hcl | Clonidine Hcl | 93 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 21 |
| Famotidine | Famotidine | 88 | 18 |
| Spironolactone | Spironolactone | 85 | 24 |
| Allopurinol | Allopurinol | 81 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 81 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 23 |
| Temazepam | Temazepam | 79 | suppressed |
| Bupropion Xl | Bupropion Hcl | 76 | 18 |
| Warfarin Sodium | Warfarin Sodium | 74 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 24 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Synthroid | Levothyroxine Sodium | 69 | 19 |
| Amiloride Hcl | Amiloride Hcl | 65 | 12 |
| Azithromycin | Azithromycin | 63 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 18 |
| Amoxicillin | Amoxicillin | 60 | 38 |
| Meloxicam | Meloxicam | 55 | 17 |
| Trazodone Hcl | Trazodone Hcl | 54 | 17 |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | suppressed |
| Mounjaro | Tirzepatide | 49 | 15 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 12 |
| Atenolol | Atenolol | 45 | 13 |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 43 | 32 |
| Diazepam | Diazepam | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 19 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Cephalexin | Cephalexin | 38 | 29 |
| Eplerenone | Eplerenone | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Clonidine | Clonidine | 33 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 11 |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Methadone Hcl | Methadone Hcl | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Pulmicort Flexhaler | Budesonide | 17 | suppressed |
| Victoza 3-Pak | Liraglutide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Latuda | Lurasidone Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $199.22 · 10 records | ABBVIE INC. | CREON, ELIQUIS, EVENITY, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, VRAYLAR, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error